Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Multiomics analysis dissects the molecular foundation of perianal fistulas associated with Crohn's disease and of cryptoglandular origin.
Journal: Journal of Crohn's & colitis
Published: June 30, 2026
Outcomes in patients with IBD stratified by risk of disease progression.
Journal: The American journal of managed care
Published: July 24, 2025
Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study.
Journal: Journal of managed care & specialty pharmacy
Published: October 29, 2024
Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
Journal: Current medical research and opinion
Published: April 08, 2024
Real-World Treatment Outcomes Associated With Early Versus Delayed Vedolizumab Initiation in Patients With Ulcerative Colitis.
Journal: Crohn's & colitis 360
Published: March 11, 2024
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY.
Journal: BMC gastroenterology
Published: November 23, 2023
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
Journal: Inflammatory bowel diseases
Published: May 03, 2023
Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort.
Journal: Journal of pediatric gastroenterology and nutrition
Published: February 22, 2023
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
Journal: Crohn's & colitis 360
Published: January 12, 2023
Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
Journal: BMC gastroenterology
Published: October 13, 2022
Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis.
Journal: BMC gastroenterology
Published: January 05, 2022
Last Updated: 09/26/2026